Marx G, Zhou H, Graves D E, Osheroff N
Department of Chemistry, University of Mississippi, University, Mississippi 38677, USA.
Biochemistry. 1997 Dec 16;36(50):15884-91. doi: 10.1021/bi971858c.
The classic DNA intercalator, ethidium, was used to probe the effects of (i) intercalation and (ii) covalent modification of the DNA on the catalytic activity of topoisomerase II. Ethidium bromide, which binds reversibly to DNA via intercalation, does not stimulate topoisomerase II-mediated DNA cleavage at concentrations up to 100 microM, indicating that the intercalative binding of this molecule to DNA is not sufficient to alter the activity of the enzyme. In contrast, covalent attachment of the photoreactive ethidium analog to DNA resulted in marked enhancement of topoisomerase II-mediated single- and double-stranded DNA cleavage. This increase in DNA cleavage was observed at very low drug binding densities (<1 drug per 10-80 base pairs) which correspond to nanomolar concentrations, as compared with other topoisomerase II poisons such as etoposide or m-AMSA which require micromolar concentrations to elicit comparable DNA cleavage levels. Over the past decade, topoisomerase II has been an important target for a variety of clinically relevant anticancer agents due to the abilities of these agents to convert this enzyme to a cellular toxin resulting in an increase in the levels of enzyme-mediated DNA breaks. Modification of DNA by covalently attaching a DNA-targeting intercalating agent (i.e., ethidium bromide) resulted in a marked shift of the cleavage/religation equilibrium of the enzyme toward the cleaved state "poison" topoisomerase II as observed by the enhancement in single- and double-stranded cleavage; thus, key insight was gained into the mechanism(s) through which DNA binding agents may influence the catalytic properties of topoisomerase II. These data demonstrate that conversion of a reversible ethidium-DNA complex to an irreversible adduct results in the transformation of an ineffective intercalating drug into a potent topoisomerase II-targeted agent. Finally, they provide support for the recently proposed "positional poisoning model" for the actions of DNA lesions and anticancer drugs on the type II enzyme.
经典的DNA嵌入剂溴化乙锭被用于探究(i)嵌入作用以及(ii)DNA的共价修饰对拓扑异构酶II催化活性的影响。溴化乙锭通过嵌入作用与DNA可逆结合,在浓度高达100微摩尔时,它不会刺激拓扑异构酶II介导的DNA切割,这表明该分子与DNA的嵌入性结合不足以改变酶的活性。相比之下,光反应性溴化乙锭类似物与DNA的共价连接导致拓扑异构酶II介导的单链和双链DNA切割显著增强。在非常低的药物结合密度(每10 - 80个碱基对少于1个药物分子)下就观察到了DNA切割的增加,这对应于纳摩尔浓度,而其他拓扑异构酶II抑制剂如依托泊苷或m - AMSA需要微摩尔浓度才能引发相当的DNA切割水平。在过去十年中,拓扑异构酶II一直是多种临床相关抗癌药物的重要靶点,因为这些药物能够将该酶转化为细胞毒素,导致酶介导的DNA断裂水平增加。通过共价连接一种靶向DNA的嵌入剂(即溴化乙锭)对DNA进行修饰,导致酶的切割/连接平衡明显向切割状态偏移,即“毒害”拓扑异构酶II,这可通过单链和双链切割的增强观察到;因此,对于DNA结合剂可能影响拓扑异构酶II催化特性的机制有了关键的认识。这些数据表明,将可逆的溴化乙锭 - DNA复合物转化为不可逆加合物会导致一种无效的嵌入药物转变为一种有效的靶向拓扑异构酶II的药物。最后,它们为最近提出的关于DNA损伤和抗癌药物对II型酶作用的“位置中毒模型”提供了支持。